Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database.
Peter E LonerganChang Wook JeongSamuel L WashingtonAnnika HerlemannScarlett Lin GomezPeter R CarrollMatthew R CooperbergPublished in: Prostate cancer and prostatic diseases (2021)
Our results support extending AS criteria more permissively to carefully selected men with PSA 10-20 ng/mL and GG 1 disease.